Cargando…
血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析
BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the survival of advanced lung adenocarcinoma patients harboring EGFR mutation. Limited to the standards of tumor tissue samples and detection methods, still some people can't...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973368/ https://www.ncbi.nlm.nih.gov/pubmed/28935011 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.09.01 |
Ejemplares similares
-
鉴定晚期肺腺癌EGFR-T790M耐药基因突变候选生物标志物
Publicado: (2020) -
肺癌血清肿瘤标志物meta分析
Publicado: (2010) -
肺癌血清肿瘤标志物的临床意义
Publicado: (2011) -
晚期肺腺癌患者一线治疗前后EGFR基因突变差异性分析
Publicado: (2018) -
多项肺系统肿瘤标志物异常在晚期肺腺癌治疗中的作用
Publicado: (2017)